Tracers / [225Ac]Ac-J591

[225Ac]Ac-J591

Also written as [Ac-225]Ac-J591; Ac-225-J591

Radionuclide: Ac-225 t½ 14284.8 min
Modality: Therapy
Production route: —
Stage: first-in-human phase I dose-escalation trial
Syntheses indexed: 2

Prostate cancer PSMA-directed radioligand therapy

What it is

Compound class: Anti-PSMA monoclonal antibody radioconjugate
Target / mechanism: Targets prostate-specific membrane antigen (PSMA) via monoclonal antibody J591 PMID 37922438
Clinical application: Radioligand (radioimmuno-) therapy for metastatic castration-resistant prostate cancer PMID 37922438
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
—	—	—	—	—	—	37922438 2024 J Clin Oncol
—	—	—	—	—	J591	33778927 2021 Curr Oncol Rep

Need this precursor?We can point you to suppliers for [225Ac]Ac-J591, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 37922438: 'To our knowledge, this is the first-in-human phase I dose-escalation trial of a single dose of 225Ac-J591 in 32 patients with pretreated progressive mCRPC demonstrated safety and preliminary efficacy signals.'.